MedTrace Logo

Channa Striatus Extract on Albumin and Hs-CRP ESRD

NCT05614362 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-11-14

No results posted yet for this study

Summary

This study is a randomised, double blind, placebo-controlled study in patients with ESRD on HD or CAPD based RRTs at Moewardi General Hospital in Surakarta, Indonesia from January to March 2021. Subjects were randomized to either a Channa striata or a placebo group and were given a three times daily dosage of 500 mg of Channa striatus extract or 500 mg maltodextrin, respectively for 21 days. Serum albumin and hs-CRP were measured at the baseline, and at the end of the study

Conditions

Interventions

DIETARY_SUPPLEMENT

Channa Striatus extract

Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient

DIETARY_SUPPLEMENT

Maltodextrin

Maltodextrin given three-times-daily for each patient

Sponsors & Collaborators

  • Universitas Sebelas Maret

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-03-01
Completion
2021-03-01

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05614362 on ClinicalTrials.gov